Oral Mucositis Prevention By Low-Level Laser Therapy in Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy: A Phase III Randomized Study
| Autor: | R.C. Villar, Reynaldo Antequera, Mauro Cabral Rosalmeida, Miriam Hatsue Honda Federico, Igor Moisés Longo Snitcovsky, Aline Gouvêa de Lima, Erlon Gil, Gilberto de Castro |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cancer Research
medicine.medical_specialty Radiation business.industry medicine.medical_treatment Head and neck cancer Cancer medicine.disease Placebo Gastroenterology Surgery Oncology Internal medicine Mucositis medicine Carcinoma Radiology Nuclear Medicine and imaging business Prospective cohort study Chemoradiotherapy Low level laser therapy |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 82:270-275 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2010.10.012 |
| Popis: | Purpose Oral mucositis is a major complication of concurrent chemoradiotherapy (CRT) in head-and-neck cancer patients. Low-level laser (LLL) therapy is a promising preventive therapy. We aimed to evaluate the efficacy of LLL therapy to decrease severe oral mucositis and its effect on RT interruptions. Methods and Materials In the present randomized, double-blind, Phase III study, patients received either gallium-aluminum-arsenide LLL therapy 2.5 J/cm 2 or placebo laser, before each radiation fraction. Eligible patients had to have been diagnosed with squamous cell carcinoma or undifferentiated carcinoma of the oral cavity, pharynx, larynx, or metastases to the neck with an unknown primary site. They were treated with adjuvant or definitive CRT, consisting of conventional RT 60–70 Gy (range, 1.8–2.0 Gy/d, 5 times/wk) and concurrent cisplatin. The primary endpoints were the oral mucositis severity in Weeks 2, 4, and 6 and the number of RT interruptions because of mucositis. The secondary endpoints included patient-reported pain scores. To detect a decrease in the incidence of Grade 3 or 4 oral mucositis from 80% to 50%, we planned to enroll 74 patients. Results A total of 75 patients were included, and 37 patients received preventive LLL therapy. The mean delivered radiation dose was greater in the patients treated with LLL (69.4 vs. 67.9 Gy, p = .03). During CRT, the number of patients diagnosed with Grade 3 or 4 oral mucositis treated with LLL vs. placebo was 4 vs. 5 (Week 2, p = 1.0), 4 vs. 12 (Week 4, p = .08), and 8 vs. 9 (Week 6, p = 1.0), respectively. More of the patients treated with placebo had RT interruptions because of mucositis (6 vs. 0, p = .02). No difference was detected between the treatment arms in the incidence of severe pain. Conclusions LLL therapy was not effective in reducing severe oral mucositis, although a marginal benefit could not be excluded. It reduced RT interruptions in these head-and-neck cancer patients, which might translate into improved CRT efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|